AI Article Synopsis
- Opioid agonist medications like methadone are the primary treatment option for opioid use disorder and help lower overdose risks when taken daily.
- Although methadone is effective, the risk of overdose spikes significantly when patients stop taking it.
- The COVID-19 pandemic has made it critical to maintain access to methadone treatment to combat the worsening overdose crisis, especially with the rise of fentanyl.
Article Abstract
Opioid agonist medication, including methadone, is considered the first-line treatment for opioid use disorder. Methadone, when taken daily, reduces the risk of fatal overdose; however, overdose risk increases following medication cessation. Amid an overdose epidemic accelerated by the proliferation of fentanyl, ensuring continuity of methadone treatment during the COVID-19 pandemic is a vital public health priority. (. 2021;111(12):2115-2117. https://doi.org/10.2105/AJPH.2021.306523).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667852 | PMC |
| http://dx.doi.org/10.2105/AJPH.2021.306523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Addiction treatment and harm reduction programs in prisons: lessons from Iran.
Int J Prison Health (2024)
December 2024
Department of addiction, School of behavioural sciences and mental health (Tehran Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran.
Purpose: Substance use disorder is one of the most prevalent health issues among prison populations. In this regard, addiction treatment and harm reduction programs have been implemented in Iranian prisons since 2002. The purpose was to describe the practical experience of implementing harm reduction programs in Iran's prisons, emphasizing the impact of policy decisions on it.
View Article and Find Full Text PDFImproving hospital care for people who use drugs: deliberative process development of a clinical guideline for opioid withdrawal management.
Harm Reduct J
November 2024
Department of Public Health, Environments & Society, London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK.
Background: Management of opioid withdrawal in hospital settings is crucial to improve treatment completion and health outcomes among patients who use opioids, such as heroin. Evidence-based clinical guidelines can support responsive provision of opioid substitution therapy (OST). In England there is no standardised application of guidance for substance dependence management across National Health Service (NHS) Hospitals.
View Article and Find Full Text PDFAdapting a Behavioral Activation Intervention for Opioid Use Disorder and Methadone Treatment Retention for Peer Delivery in a Low-Resource Setting: A Case Series.
Cogn Behav Pract
November 2024
University of Maryland, College Park.
While methadone treatment (MT) is effective in treating opioid use disorder (OUD), retention remains an issue nationwide, especially among low-income, minoritized populations. Peer recovery specialists (PRSs), individuals with lived substance use experience, are particularly well suited to support vulnerable populations, though often are not trained in delivering evidence-based interventions. Thus, our team developed a Type 1 hybrid effectiveness-implementation open-label pilot trial to evaluate the effectiveness of PRS-delivered BA (Peer Activate) in improving MT retention and establish feasibility, acceptability and PRS fidelity of the intervention.
View Article and Find Full Text PDF"Yeah, this is not going to work for me"-The impact of federal policy restrictions on methadone continuation upon release from jail or prison.
J Subst Use Addict Treat
January 2025
Duke University School of Medicine, Department of Population Health Sciences, United States.
Introduction: Individuals impacted by the criminal-legal system face increased risk of opioid overdose. Medications for opioid use disorder (MOUD) provide a life-saving intervention. Multiple barriers prevent access to MOUD, including federal policies regulating opioid treatment programs (OTPs).
View Article and Find Full Text PDFHealth service utilization, substance use treatment response, and death in patients with opioid use disorder and comorbid hepatitis C findings from prospective cohort study with administrative database linkage.
J Subst Use Addict Treat
December 2024
Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada.
Background: Among patients with opioid use disorder (OUD), high rates of overdose and death have been reported in subgroups with Hepatitis C Virus (HCV). Evidence on the comorbid effect of HCV on clinical and substance use trajectories has been limited by small sample sizes, short follow-up, and heavy reliance on administrative data which lacks granularity on important prognostic factors. Additionally, few studies include populations on substance use treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!